Saxenda Efficacy Reports from Real Users

What the Clinical Data Promise

The SCALE Obesity and Prediabetes trial (N=3,731) remains the largest randomized controlled study of Saxenda. Participants receiving liraglutide 3 mg daily lost a mean of 8.0% of body weight at 56 weeks, compared with 2.6% in the placebo group [1]. Among completers, 63.2% lost at least 5% of their starting weight, and 33.1% lost at least 10% [1].

These numbers set the benchmark. But trial participants received structured dietary counseling, exercise guidance, and regular follow-up visits that most real-world patients do not get. The SCALE population also skewed toward motivated enrollees who passed screening and accepted randomization, introducing a selection filter that favors better outcomes. A 2020 post-hoc analysis published in Obesity found that early responders (those who lost at least 4% of body weight by week 16) accounted for a disproportionate share of the trial's headline results, while non-responders saw minimal benefit beyond that point [2]. The FDA label itself recommends discontinuing Saxenda if a patient has not lost at least 4% of baseline weight by 16 weeks [3].

What Reddit and Forum Users Report

User-generated reviews across Reddit (r/liraglutide, r/loseit, r/Saxenda), Drugs.com, and other platforms paint a more variable picture than the controlled trial data. Selection bias cuts both ways here: people who had dramatic results or terrible experiences are more likely to post than those with moderate, unremarkable outcomes.

Common themes emerge across hundreds of posts. Users frequently describe the first two to four weeks as the hardest period, dominated by nausea, headaches, and appetite changes that precede any visible weight loss. One Reddit user (r/Saxenda, 2024) wrote: "Weeks 1 through 3 I lost nothing and felt awful. By week 6 at the 1.8 mg dose, I'd dropped 11 pounds and the nausea had settled to something manageable." Another Drugs.com reviewer reported: "I lost 42 pounds in 7 months on Saxenda. The first month was rough with stomach issues, but once my body adjusted, my appetite just... quieted down."

Not all reports are positive. A recurring complaint involves weight loss stalling after an initial drop. Users on r/loseit describe losing 15 to 25 pounds in the first three months, then hitting a plateau that persists despite remaining on the full 3.0 mg dose. Others note that weight returns quickly after stopping the medication. A Drugs.com review from a verified patient stated: "Lost 30 lbs in 5 months, regained 22 within 4 months of stopping. The drug works while you take it. That's the honest truth."

Drugs.com Review Patterns

Drugs.com aggregates structured user reviews with numerical ratings, providing a rough quantitative snapshot. As of early 2026, Saxenda holds an average rating of approximately 5.8 out of 10, based on over 900 submitted reviews for weight management. This places it below semaglutide 2.4 mg (Wegovy), which averages closer to 7.5 out of 10 on the same platform, but above older agents like orlistat.

The distribution is bimodal. A large cluster of reviewers rate Saxenda 8, 9, or 10 out of 10 and describe life-changing weight loss. An equally visible cluster rates it 1, 2, or 3 out of 10 and cites intolerable nausea, no meaningful weight loss, or rapid regain. Relatively few reviews sit in the 4 to 6 range. This pattern is consistent with the pharmacological reality that GLP-1 receptor agonists produce strong appetite suppression in some individuals and minimal effect in others, with genetic variation in GLP-1 receptor expression likely playing a role [4].

Reviewers who rate Saxenda highly tend to mention specific behavioral changes: reduced food noise, smaller portions feeling satisfying, and decreased cravings for sugar and processed food. Those who rate it poorly often describe persistent gastrointestinal symptoms that never fully resolve or weight loss of less than 5 pounds over several months.

How Real-World Results Compare to Trial Data

Observational studies confirm that real-world Saxenda outcomes fall short of clinical trial benchmarks. A 2021 retrospective cohort study published in Obesity Science & Practice (N=2,144) found that patients prescribed liraglutide 3 mg in routine clinical settings lost a mean of 5.2% of body weight at 6 months, compared with the 8.0% seen in SCALE at 12 months [5]. Only 40.8% achieved the clinically meaningful threshold of 5% or greater weight loss at 6 months.

Several factors explain this gap. Trial adherence rates exceed what happens in practice, where patients miss doses, abandon the titration schedule due to side effects, or discontinue before reaching the full 3.0 mg maintenance dose. Insurance coverage barriers also play a role. Saxenda's list price (approximately $1,300 to $1,400 per month without insurance) forces some patients to stop treatment prematurely. A CDC analysis of anti-obesity medication utilization noted that cost and coverage gaps remain the primary drivers of early discontinuation across the GLP-1 class [6].

Real-world data also show higher rates of gastrointestinal side effects leading to dropout. While SCALE reported a 6.4% discontinuation rate due to adverse events, practice-based studies suggest 15 to 25% of patients stop Saxenda within the first 8 weeks because of nausea, vomiting, or diarrhea [5].

The Nausea Factor

Nausea dominates user reviews more than any other topic. In the SCALE trial, 39.3% of liraglutide-treated participants reported nausea versus 13.8% on placebo [1]. The side effect typically peaks during dose escalation (weeks 1 through 5) and resolves or diminishes for most patients by weeks 8 to 12.

Forum users confirm this timeline but emphasize that "resolves" is relative. Many describe a low-grade queasiness that never fully disappears, particularly after larger meals or high-fat foods. Others report that nausea becomes the mechanism of action itself: they eat less because eating makes them feel sick, not because they feel genuinely satisfied.

Dr. Caroline Apovian, an obesity medicine specialist at Brigham and Women's Hospital, has noted: "The GI side effects of GLP-1 agonists are dose-dependent and typically transient. Slower titration can help, and we counsel patients that the first month is rarely representative of their long-term experience" [7].

Strategies that forum users report helpful include eating smaller meals, avoiding greasy food, staying hydrated, and taking the injection at bedtime rather than in the morning. Some users describe success with a slower-than-label titration schedule (increasing by 0.6 mg every two weeks instead of weekly), though this extends the time to reach the full therapeutic dose.

Saxenda vs. Newer GLP-1 Agonists in User Perception

A significant portion of recent Saxenda discussion occurs in the context of comparison with semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo [8], nearly doubling the efficacy benchmark set by Saxenda.

Reddit threads increasingly frame Saxenda as the "older option" or a fallback for patients who cannot access or tolerate semaglutide. Users who switched from Saxenda to Wegovy frequently report greater appetite suppression and faster weight loss on the newer drug. One r/Semaglutide user described the transition: "Saxenda got me 18 pounds in 4 months. Wegovy got me 32 pounds in the same timeframe. The daily injection was also just annoying compared to once a week."

This comparison creates a perception gap that may not fully reflect clinical reality. For some patients, liraglutide's shorter half-life (13 hours versus 7 days for semaglutide) means faster washout of side effects if problems arise. The daily dosing also allows more granular dose adjustment. A 2022 systematic review in The Lancet Diabetes & Endocrinology confirmed semaglutide's superior weight loss efficacy but noted that head-to-head discontinuation rates were comparable between the two agents [9].

Who Reports the Best Results

Across both clinical data and user reviews, certain patient profiles consistently report stronger outcomes with Saxenda. Patients with higher baseline BMI (35+) tend to lose a greater absolute number of pounds, though percentage weight loss remains similar across BMI categories [1]. Patients with insulin resistance or prediabetes appear to derive particular benefit, consistent with GLP-1's physiological role in glucose metabolism. The SCALE Diabetes sub-study (N=846) showed that liraglutide 3 mg improved HbA1c by 1.3 percentage points alongside weight loss in patients with type 2 diabetes [10].

Forum users who describe the best results almost universally mention combining Saxenda with structured dietary changes and regular exercise. The drug appears most effective as an appetite management tool layered on top of behavioral modifications, not as a standalone intervention. Users who describe taking Saxenda while making no dietary changes consistently report disappointing outcomes.

Patients who respond early tend to respond well long-term. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends evaluating response at 12 to 16 weeks and discontinuing medications that have not produced meaningful weight loss by that point [11]. This recommendation aligns with user reports: those who see less than 3 to 4% weight loss in the first 16 weeks rarely describe catching up later.

Weight Regain After Stopping

Weight regain is the most emotionally charged topic in Saxenda user communities. The SCALE Maintenance trial demonstrated that patients who discontinued liraglutide after 56 weeks regained approximately two-thirds of the weight they had lost within 12 months [12]. Forum reports are consistent with this finding and sometimes more dramatic.

Users describe a rapid return of appetite, food cravings, and previous eating patterns within days to weeks of their last injection. The speed of regain appears to depend on whether the patient developed sustainable dietary habits while on the medication. Those who used Saxenda as a window to build new behaviors report slower or partial regain. Those who relied on the drug's appetite-suppressing effect without behavioral change report nearly complete regain.

This pattern is not unique to Saxenda. A NIH-funded review of anti-obesity medications concluded that obesity is a chronic disease requiring ongoing treatment, much like hypertension or diabetes, and that discontinuation of effective pharmacotherapy predictably leads to disease recurrence [13].

Reading User Reviews Without Getting Misled

Patient forums and review sites provide real signal, but interpreting them requires understanding their limitations. Response bias skews online reviews toward extreme experiences. Sample sizes are small: even a platform with 900 reviews represents a tiny fraction of the millions of Saxenda prescriptions filled since 2015. Dosing details, adherence patterns, and comorbidities are rarely disclosed in user posts.

The most reliable signal from user reviews is qualitative, not quantitative. Forum discussions are valuable for understanding the lived experience of dose titration, the texture of side effects that clinical papers describe in sterile percentages, and the psychological impact of appetite changes. They are poor sources for estimating your personal probability of success.

A reasonable synthesis of the available evidence: Saxenda produces clinically meaningful weight loss (5% or more) in roughly 50 to 60% of patients who tolerate the full dose for at least 16 weeks, with a mean expectation of 5 to 8% body weight reduction at one year in real-world settings. Patients who respond early and combine the medication with dietary and exercise modifications report the best sustained outcomes.